The US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee will review the Biologics License Application (BLA) for CTL019 (tisagenlecleucel-T) in relapsed and refractory (r/r) pediatric and young adult patients with B-cell acute lymphoblastic leukemia on July 12.
Swiss pharma giant Novartis (NOVN: VX) announced in March that the FDA had accepted for review the filing in this indication for CTL019, an investigational chimeric antigen receptor T cell (CAR-T) therapy, and granted priority review status.
Along with the likes of Kite Pharma (Nasdaq: KITE) and Juno Therapeutics (Nasdaq: JUNO), Novartis is leading the way in the emerging field of CAR-T investigational therapies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze